Last update Sept. 4, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
نيتوبيتانت is Netupitant in Arabic.Is written in other languages:
نيتوبيتانت belongs to these groups or families:
Main tradenames from several countries containing نيتوبيتانت in its composition:
|VD||28.3 ± 12.9||l/Kg|
|Tmax||5 (3 - 6)||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Aprepitant is a neurokinin-1 receptor antagonist. It is used for the prevention and treatment of nausea and vomiting caused by chemotherapy and surgery. Oral administration in combination with palonosetron.
On latest update relevant data on breastfeeding was not found.
Its very high volume of distribution, and its very high plasma protein binding make excretion into breast milk unlikely.
Side effects are few and usually mild.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.